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Neurostimulation is an emerging treatment for neurological diseases.
Electrical pulses are administered directly to, or in the surrounding area of, nervous tissue in order to manipulate a pathological substrate and to achieve a symptomatic or even curative therapeutic effect. Electrical stimulation of the 10th cranial nerve, or vagus nerve stimulation (VNS), is an extracranial form of neurostimulation that was developed in the 1980s. 1 In the past decade it has become a valuable option in the therapeutic armamentarium for patients with refractory epilepsy and it is currently routinely available in epilepsy centres worldwide. Through an implanted device and electrode, electrical pulses are administered to the afferent fibres of the left vagus nerve in the neck. It is indicated in patients with refractory epilepsy who are unsuitable candidates for epilepsy surgery or who have had insufficient benefit from such a treatment.
Since the first human implant of the VNS Therapy™ device in 1989, over 50,000 patients have been treated with VNS worldwide. As with many antiepileptic treatments, the clinical application of VNS preceded the elucidation of its mechanism of action (MOA). Following a limited number of animal experiments in dogs and monkeys investigating safety and efficacy, the first human trial was carried out. 2 One-third of patients with refractory epilepsy treated with VNS were responders and 7-8% became seizure-free. 3 It remains unclear what type of epileptic seizures or syndromes respond optimally to VNS. Elucidation of the MOA may improve clinical outcome, as it may provide strategies for the optimisation of stimulation parameters and the identification of suitable VNS candidates.
The Anatomical Basis of Vagus Nerve Stimulation
The vagus nerve is a mixed cranial nerve that consists of ~80% afferent fibres originating from the heart, aorta, lungs and gastrointestinal tract and ~20% efferent fibres that provide parasympathetic innervation of these structures and also innervate the voluntary striated muscles of the larynx and pharynx. [4] [5] [6] There are direct neural projections into the raphe nucleus, which is the major source of serotonergic neurons, and indirect projections to the locus coeruleus and A5 nuclei, which contain noradrenegic neurons. Finally, there are numerous diffuse cortical connections.
The diffuse pathways of the vagus nerve mediate important visceral reflexes such as coughing, vomiting, swallowing and control of blood pressure and heart rate. Heart rate is mostly influenced by the right vagus nerve, which has dense projections primarily to the atria of the heart. 7 Relatively few specific functions of the vagus nerve have been well characterised. The vagus nerve is often considered to be protective, defensive and relaxing. This primary function is exemplified by the lateral line system in fish, the early precedent of the autonomic nervous system. 8 The control of homeostatic functions by the central nervous system in these earlier life forms was limited to the escape and avoidance of perturbing stimuli or suboptimal conditions. Its complex anatomical distribution has earned the vagus nerve its name, as 'vagus' is the Latin word for wanderer. These two facts together inspired Andrews and Lawes to suggest the name 'great wandering protector'. 8
How to Investigate the Mechanism of Action of Vagus Nerve Stimulation
The basic hypothesis of the MOA was based on the knowledge that the 10th cranial nerve afferents have numerous projections within the central nervous system and that, in this way, action potentials generated in vagal afferents have the potential to affect the entire organism. 9 To date, the precise MOA of VNS and how it suppresses seizures remains to be elucidated. Crucial questions with regard to the MOA of VNS occur at different levels.
Nerve Fibres, Central Nervous System

Structures and Neurotransmitters
VNS aims to induce action potentials within the different types of fibres that constitute the nerve at the cervical level. The question remains: which fibres are responsible and/or necessary for its seizure-suppressing effect?
Unidirectional stimulation, activating afferent vagal fibres, is preferred, as epilepsy is considered a disease with cortical origin, and efferent stimulation may cause adverse effects. The next step is to identify central nervous system structures located on the anatomical pathways from the cervical part of the vagus nerve up to the cortex that play a functional role in the MOA of VNS. 
Nerve Fibres, Central Nervous System
Structures and Neurotransmitters
From the extensive body of research on the MOA, it is now assumed that effective stimulation in humans is primarily mediated by afferent vagal Aand B-fibres. 11, 12 Unilateral stimulation affects both cerebral hemispheres, as shown in several functional imaging studies. [13] [14] [15] Brainstem and intracranial structures have been identified and include the locus coeruleus, the nucleus of the solitary tract, the thalamus and limbic structures. [16] [17] [18] [19] Neurotransmitters playing a role may involve the major inhibitory neurotransmitter GABA, but also serotoninergic and adrenergic systems. 20, 21 More recently, Neese et al. found that VNS following experimental brain injury in rats protects cortical GABAergic cells from death. 22 A SPECT study in humans before and after one year of VNS showed a normalisation of GABA A receptor density in the individuals with a clear therapeutic response to VNS. 23 Follesa et al. showed an increase of norepinephrine concentration in the prefrontal cortex of the rat brain after acute VNS. 24 An increased norepinephrine concentration after VNS has also been measured in the hippocampus 25 and amygdala. 26 Currently, VNS as a neuroimmunomodulatory treatment is being explored. As the vagus nerve plays a critical role in the signalisation and modulation of inflammatory processes, the so-called anti-inflammatory pathway, this could represent a new modality in the MOA of VNS for epilepsy. 27, 28 Recent experiments have shown that VNS significantly increases cortisol levels in freely moving rats. 29 Antiseizure, Antiepileptic and
Antiepileptogenic Treatments
Early animal experiments in acute seizure models suggested an antiseizure effect of VNS. McLachlan found that applying VNS at the beginning of a pentylenetetrazole (PTZ)-induced seizure significantly shortened the seizure. 30 Woodbury and Woodbury described the beneficial effect of VNS in preventing or reducing PTZ-induced clonic seizures and electrically induced tonic-clonic seizures in rats. 31 Zabara found that VNS interrupts or abolishes motor seizures in canines induced by strychnine. 32 In our own group, VNS significantly increased the seizure threshold for focal motor seizures in the cortical stimulation model. 33 Also in the literature on humans, there is clear evidence of an acute abortive effect of VNS. The magnet feature allows a patient to terminate an upcoming seizure. 34 In addition, a few case reports describe the use of VNS for refractory status epilepticus in paediatric and adult patients. 35, 36 However, in the clinical trials with VNS, many patients did not regularly selftrigger the device at the time of a seizure and still showed good response to VNS. In addition, VNS is administered in an intermittent way, and it appears that seizures occurring during the VNS off-time are also affected. This intermittent method of stimulation is insufficient to explain the reduction of seizures on the basis of abortive effects alone and suggests a true preventative or so-called antiepileptic effect of VNS. The fact that VNS influences seizures at a time when stimulation is in the off-mode has also been shown in many animal and human experiments. In 1985 Zabara reported that seizure control was extended well beyond the end of the stimulation period. Stimulation for one minute could produce seizure suppression for five minutes in canines. 32, 37 Naritoku and Mikels showed that VNS pre-treatment during one and 60 minutes, prior to administration of the seizure-triggering stimulation, significantly reduced the duration of behavioural seizures and the duration of afterdischarges in amygdala kindled rats. 38 In a study by Takaya et al. VNS was discontinued before induction of PTZ seizures that were significantly shortened in duration. 39 In addition, repetition of stimuli increased VNS efficacy, suggesting that efficacy of intermittent stimulation improves with long-term use. Zagon and Kemeny found that VNS-induced slow hyperpolarisation in the parietal cortex of the rat outlasted a 20-second VNS train by 15 seconds. 11 McLachlan found that interictal spike frequency was significantly decreased or abolished after 20 seconds of VNS in rats for a variable duration, usually around 60 seconds to three minutes after stimulation discontinuation. 40 Recent data in human EEG studies show a decrease in interictal epileptiform discharges, both in an acute form and after long-term follow-up. 41, 42 The fact that seizures reoccur after the end of battery life has been reached is a strong argument against VNS having an antiepileptogenic effect. However, as progress in the development of more relevant animal models for epilepsy has been made, the antiepileptogenic potential of neurostimulation in general is being fully explored, and some promising results have been reported, e.g. in the kindling model. 38, 43 In literature on humans, one case report described long-lasting seizure control after explantation of the VNS device. 44 The basis for the combined acute and more chronic effects of VNS most likely involves recruitment of different neuronal pathways and networks.
The more chronic effects are thought to be a reflection of modulatory changes in subcortical site-specific synapses, with the potential to influence larger cortical areas. In the complex human brain these neuromodulatory processes require time to build up. Once installed, certain antiepileptic neural networks may be more easily recruited, e.g. by changing stimulation parameters that may then be titrated to the individual need of the patient.
This raises hope for potential antiepileptogenic properties of VNS using long-term optimised stimulation parameters that may affect and potentially reverse pathological processes that have been installed over a long period of time. However, from a clinical point of view, as yet VNS cannot be considered a curative treatment.
Conclusion
Despite the fact that VNS is accepted in epilepsy centres worldwide as a valuable and reliable therapeutic option for patients who are unsuitable candidates for resective surgery, some specific issues remain to counteract its full therapeutic potential. On the basis of currently available data, the responder rate in patients treated with VNS is not substantially higher compared with recently marketed antiepileptic drugs. 
